255 related articles for article (PubMed ID: 32966866)
1. FABP5 as a novel molecular target in prostate cancer.
O'Sullivan SE; Kaczocha M
Drug Discov Today; 2020 Sep; ():. PubMed ID: 32966866
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid-binding protein 5 (FABP5) promotes lipolysis of lipid droplets, de novo fatty acid (FA) synthesis and activation of nuclear factor-kappa B (NF-κB) signaling in cancer cells.
Senga S; Kobayashi N; Kawaguchi K; Ando A; Fujii H
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Sep; 1863(9):1057-1067. PubMed ID: 29906613
[TBL] [Abstract][Full Text] [Related]
3. Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma.
Li Y; Lee W; Zhao ZG; Liu Y; Cui H; Wang HY
World J Clin Oncol; 2024 Jan; 15(1):130-144. PubMed ID: 38292656
[TBL] [Abstract][Full Text] [Related]
4. The cancer-promoting gene fatty acid-binding protein 5 (FABP5) is epigenetically regulated during human prostate carcinogenesis.
Kawaguchi K; Kinameri A; Suzuki S; Senga S; Ke Y; Fujii H
Biochem J; 2016 Feb; 473(4):449-61. PubMed ID: 26614767
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
[TBL] [Abstract][Full Text] [Related]
6. The emerging role of fatty acid binding protein 5 (FABP5) in cancers.
George Warren W; Osborn M; Yates A; Wright K; O'Sullivan SE
Drug Discov Today; 2023 Jul; 28(7):103628. PubMed ID: 37230284
[TBL] [Abstract][Full Text] [Related]
7. FABP5 coordinates lipid signaling that promotes prostate cancer metastasis.
Carbonetti G; Wilpshaar T; Kroonen J; Studholme K; Converso C; d'Oelsnitz S; Kaczocha M
Sci Rep; 2019 Dec; 9(1):18944. PubMed ID: 31831821
[TBL] [Abstract][Full Text] [Related]
8. FABP5 regulates the proliferation of clear cell renal cell carcinoma cells via the PI3K/AKT signaling pathway.
Lv Q; Wang G; Zhang Y; Han X; Li H; Le W; Zhang M; Ma C; Wang P; Ding Q
Int J Oncol; 2019 Apr; 54(4):1221-1232. PubMed ID: 30968158
[TBL] [Abstract][Full Text] [Related]
9. FABP5 correlates with poor prognosis and promotes tumor cell growth and metastasis in cervical cancer.
Wang W; Chu HJ; Liang YC; Huang JM; Shang CL; Tan H; Liu D; Zhao YH; Liu TY; Yao SZ
Tumour Biol; 2016 Nov; 37(11):14873-14883. PubMed ID: 27644245
[TBL] [Abstract][Full Text] [Related]
10. FABP5 Inhibition against
M Swamynathan M; Mathew G; Aziz A; Gordon C; Hillowe A; Wang H; Jhaveri A; Kendall J; Cox H; Giarrizzo M; Azabdaftari G; Rizzo RC; Diermeier SD; Ojima I; Bialkowska AB; Kaczocha M; Trotman LC
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201488
[TBL] [Abstract][Full Text] [Related]
11. A novel fatty acid-binding protein 5-estrogen-related receptor α signaling pathway promotes cell growth and energy metabolism in prostate cancer cells.
Senga S; Kawaguchi K; Kobayashi N; Ando A; Fujii H
Oncotarget; 2018 Aug; 9(60):31753-31770. PubMed ID: 30167092
[TBL] [Abstract][Full Text] [Related]
12. FABP5 can substitute for androgen receptor in malignant progression of prostate cancer cells.
Naeem AA; Abdulsamad SA; Zeng H; He G; Jin X; Zhang J; Alenezi BT; Ma H; Rudland PS; Ke Y
Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38131188
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid-binding protein 5 function in hepatocellular carcinoma through induction of epithelial-mesenchymal transition.
Ohata T; Yokoo H; Kamiyama T; Fukai M; Aiyama T; Hatanaka Y; Hatanaka K; Wakayama K; Orimo T; Kakisaka T; Kobayashi N; Matsuno Y; Taketomi A
Cancer Med; 2017 May; 6(5):1049-1061. PubMed ID: 28374947
[TBL] [Abstract][Full Text] [Related]
14. FABP5 is correlated with poor prognosis and promotes tumour cell growth and metastasis in clear cell renal cell carcinoma.
Wu G; Xu Y; Wang Q; Li J; Li L; Han C; Xia Q
Eur J Pharmacol; 2019 Nov; 862():172637. PubMed ID: 31491402
[TBL] [Abstract][Full Text] [Related]
15. Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter.
Forootan FS; Forootan SS; Gou X; Yang J; Liu B; Chen D; Al Fayi MS; Al-Jameel W; Rudland PS; Hussain SA; Ke Y
Oncotarget; 2016 Feb; 7(8):9322-39. PubMed ID: 26814431
[TBL] [Abstract][Full Text] [Related]
16. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.
Powell CA; Nasser MW; Zhao H; Wochna JC; Zhang X; Shapiro C; Shilo K; Ganju RK
Oncotarget; 2015 Mar; 6(8):6373-85. PubMed ID: 25779666
[TBL] [Abstract][Full Text] [Related]
17. Fatty acid-binding protein 5 (FABP5)-related signal transduction pathway in castration-resistant prostate cancer cells: a potential therapeutic target.
Naeem AA; Abdulsamad SA; Rudland PS; Malki MI; Ke Y
Precis Clin Med; 2019 Oct; 2(3):192-196. PubMed ID: 35694437
[TBL] [Abstract][Full Text] [Related]
18. Fatty-acid-binding protein inhibition produces analgesic effects through peripheral and central mechanisms.
Peng X; Studholme K; Kanjiya MP; Luk J; Bogdan D; Elmes MW; Carbonetti G; Tong S; Gary Teng YH; Rizzo RC; Li H; Deutsch DG; Ojima I; Rebecchi MJ; Puopolo M; Kaczocha M
Mol Pain; 2017 Jan; 13():1744806917697007. PubMed ID: 28326944
[TBL] [Abstract][Full Text] [Related]
19. FABP5 promotes lymph node metastasis in cervical cancer by reprogramming fatty acid metabolism.
Zhang C; Liao Y; Liu P; Du Q; Liang Y; Ooi S; Qin S; He S; Yao S; Wang W
Theranostics; 2020; 10(15):6561-6580. PubMed ID: 32550890
[TBL] [Abstract][Full Text] [Related]
20. Truxillic acid monoamides as fatty acid binding protein 5 inhibitors.
Zhu C; Schutz L; Jayanetti K; Takemura K; Doswell F; Wang L; Ojima I; Kaczocha M
Bioorg Med Chem; 2023 Oct; 94():117464. PubMed ID: 37708641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
